Antenatal Exposure to Magnesium Sulfate and Neuroprotection in Preterm Infants

Obstetrics and Gynecology Clinics of North America

Volumn 38, Issue 2, 2011, Pages 351-366

  Costantine, Maged M ^a   Drever, Nathan ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Cerebral palsy; Magnesium sulfate; Neuroprotection; Pregnancy

Indexed keywords

MAGNESIUM SULFATE; PLACEBO;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CELL DAMAGE; CEREBRAL PALSY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; ECLAMPSIA; GESTATIONAL AGE; HEMODYNAMICS; HUMAN; INFANT; MEMBRANE STABILIZATION; META ANALYSIS (TOPIC); NERVE INJURY; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PREMATURE LABOR; PREMATURITY; PRENATAL DRUG EXPOSURE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT; VERY LOW BIRTH WEIGHT;

CEREBRAL PALSY; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MAGNESIUM SULFATE; NEUROPROTECTIVE AGENTS; PREGNANCY; PRENATAL CARE; TOCOLYTIC AGENTS;

EID: 79955967563     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2011.02.019     Document Type: Review

References (55)

1. Hagberg B., Hagberg G., Beckung E., et al. Changing panorama of cerebral palsy in Sweden. VIII. Prevalence and origin in the birth year period 1991-94. Acta Paediatr 2001, 90:271-277.
2. Yeargin-Allsopp M., Van Naarden Braun K., Doernberg N.S., et al. Prevalence of cerebral palsy in 8-year-old children in three areas of the United States in 2002: a multisite collaboration. Pediatrics 2008, 121:547-554.
3. Jacobsson B., Hagberg G., Hagberg B., et al. Cerebral palsy in preterm infants: a population-based case-control study of antenatal and intrapartal risk factors. Acta Paediatr 2002, 91:946-951.
4. Clark S.M., Ghulmiyyah L.M., Hankins G.D. Antenatal antecedents and the impact of obstetric care in the etiology of cerebral palsy. Clin Obstet Gynecol 2008, 51:775-786.
5. Nelson K.B., Grether J.K. Causes of cerebral palsy. Curr Opin Pediatr 1999, 11:487-491.
6. Honeycutt A., Dunlap L., Chen H., et al. Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment-United States 2003. MMWR Morb Mortal Wkly Rep 2004, 53:57-59.
7. Hankins G.D., Speer M. Defining the pathogenesis and pathophysiology of neonatal encephalopathy and cerebral palsy. Obstet Gynecol 2003, 102:628-636.
8. Keogh J.M., Badawi N. The origins of cerebral palsy. Curr Opin Neurol 2006, 19:129-134.
9. Stanley F., Blair E., Alberman E. Cerebral palsies: epidemiology and causal pathways 2000, MacKeith Press, London, p. 22-39.
10. Murphy D.J., Sellers S., MacKenzie I.Z., et al. A case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Lancet 1995, 346:1449-1454.
11. Kent A., Lomas F., Hurrion, et al. Antenatal steroids may reduce adverse neurologic outcome following chorioamnionitis: neurodevelopmental outcome and chorioamnionitis in premature infants. J Paediatr Child Health 2005, 41:186-190.
12. Ribiani E., Rosati A., Romanelli M., et al. Perinatal infections and cerebral palsy. Minerva Ginecol 2007, 59:151-157.
13. de Hann H.H., Gunn A.J., Williams C.E., et al. Magnesium sulfate therapy during asphyxia in near-term fetal lambs does not compromise the fetus but does not reduce cerebral injury. Am J Obstet Gynecol 1997, 176:18-27.
14. MacDonald R.L., Curry D.J., Aihara Y., et al. Magnesium and experimental vasospasm. J Neurosurg 2004, 100:106-110.
15. Schiff S.J., Somjen G.G. Hyperexcitability following moderate hypoxia in hippocampal tissue slices. Brain Res 1985, 337:337-340.
16. Wyatt J.S., Edwards A.D., Azzopardi D., et al. Magnetic resonance and near infrared spectroscopy for investigation of perinatal hypoxic-ischaemic brain injury. Arch Dis Child 1989, 64:953-963.
17. Volpe J.J. Perinatal brain injury: from pathogenesis to neuroprotection. Ment Retard Dev Disabil Res Rev 2001, 7:56-64.
18. Grow J., Barks J.D. Pathogenesis of hypoxic-ischemic cerebral injury in the term infant: current concepts. Clin Perinatol 2002, 29:585-602.
19. Sang N., Meng Z. Blockade by magnesium of sodium currents in acutely isolated hippocampal CA1 neurons of rat. Brain Res 2002, 952:218-221.
20. Goñi-de-Cerio F., Alvarez A., Alvarez F.J., et al. MgSO4 treatment preserves the ischemia-induced reduction in S-100 protein without modification of the expression of endothelial tight junction molecules. Histol Histopathol 2009, 24:1129-1138.
21. McDonald J.W., Silverstein F.S., Johnston M.V. Magnesium reduces N-methyl-D-aspartate (NMDA)-mediated brain injury in perinatal rats. Neurosci Lett 1990, 109:234-238.
22. Marret S., Gressens P., Gadisseux J.F., et al. Prevention by magnesium of excitotoxic neuronal death in the developing brain: an animal model for clinical intervention studies. Dev Med Child Neurol 1995, 37:473-484.
23. Palmer C. Hypoxic-ischemic encephalopathy. Therapeutic approaches against microvascular injury, and role of neutrophils, PAF, and free radicals. Clin Perinatol 1995, 22:481-517.
24. Thordstein M., Bågenholm R., Thiringer K., et al. Scavengers of free oxygen radicals in combination with magnesium ameliorate perinatal hypoxic-ischemic brain damage in the rat. Pediatr Res 1993, 34:23-26.
25. Spandou E., Soubasi V., Papoutsopoulou S., et al. Neuroprotective effect of long-term MgSO4 administration after cerebral hypoxia-ischemia in newborn rats is related to the severity of brain damage. Reprod Sci 2007, 14:667-677.
26. Hagan P., Barks J.D., Yabut M., et al. Adenovirus-mediated over-expression of interleukin-1 receptor antagonist reduces susceptibility to excitotoxic brain injury in perinatal rats. Neuroscience 1996, 75:1033-1045. c.
27. Yamasaki Y., Shozurhara H., Onodera H., et al. Blocking of interleukin-1 activity is a beneficial approach to ischemia brain edema formation. Acta Neurochir Suppl 1994, 60:300-302.
28. Shogi T., Miyamoto A., Ishiguro S., et al. Enhanced release of IL-1beta and TNF-alpha following endotoxin challenge from rat alveolar macrophages cultured in low-Mg(2+) medium. Magnes Res 2003, 16:111-119.
29. Burd I., Breen K., Friedman A., et al. Magnesium sulfate reduces inflammation-associated brain injury in fetal mice. Am J Obstet Gynecol 2010, 202:292. e1-9.
30. Nelson K.B., Grether J.K. Can magnesium sulfate reduce the risk of cerebral palsy in very low birth weight infants?. Pediatrics 1995, 95:263-269.
31. Hauth J.C., Goldenberg R.L., Nelson K.G., et al. Reduction of cerebral palsy with maternal MgSO4 treatment in newborns weighing 500-1000 g. Am J Obstet Gynecol 1995, 172:419.
32. Schendel D.E., Berg C.J., Yeargin-Allsopp M., et al. Prenatal magnesium sulfate exposure and the risk of CP or mental retardation among very-low-birth-weight children aged 3 to 5 years. JAMA 1996, 276:1805-1810.
33. Finesmith R.B., Roche K., Yellin P.B., et al. Effect of magnesium sulfate on the development of cystic periventricular leukomalacia in preterm infants. Am J Perinatol 1997, 14:303-307.
34. Canterino J.C., Verma U.L., Visintainer P.F., et al. Maternal magnesium sulfate and the development of neonatal periventricular leukomalacia and intraventricular hemorrhage. Obstet Gynecol 1999, 93:396-402.
35. O'Shea T.M., Klinepeter K.I., Dillard R.G. Prenatal events and the risk of cerebral palsy in very low birth weight infants. Am J Epidemiol 1998, 147:362-369.
36. Paneth N., Jetton J., Pinto-Martin J., et al. The Neonatal Brain Hemorrhage Study Analysis Group. Magnesium sulfate in labor and risk of neonatal brain lesions and cerebral palsy in low birth weight infants. Pediatrics 1997, 99:E1.
37. Leviton A., Paneth N., Susser M., et al. Maternal receipt of magnesium sulfate does not seem to reduce the risk of neonatal white matter damage. Pediatrics 1997, 99:E2.
38. Boyle C.A., Yeargin-Allsopp M.M., Schendel D.E., et al. Tocolytic magnesium sulfate exposure and risk of cerebral palsy among children with birth weights less than 1,750 grams. Am J Epidemiol 2000, 152:120-124.
39. Grether J.K., Hoogstrate J., Walsh-Greene E., et al. Magnesium sulfate for tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia. Am J Obstet Gynecol 2000, 183:717-725.
40. Wiswell T.E., Graziani L.J., Caddell J.L., et al. Maternally administered magnesium sulfate protects against early brain injury and long term adverse neurodevelopmental outcomes in premature infants: a prospective study. Pediatr Res 1996, 39:253A.
41. Mittendorf R., Dambrosia J., Pryde P.G., et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol 2002, 186:1111-1118.
42. Crowther C.A., Hiller J.E., Doyle L.W., et al. Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003, 290:2669-2676.
43. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG 2007, 114:289-299. Magpie Trial Follow-Up Study Collaborative Group.
44. Marret S., Marpeau L., Zupan-Simunek V., et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. BJOG 2007, 114:310-318. PREMAG Trial Group.
45. Rouse D.J., Hirtz D.G., Thom E., et al. A randomized trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008, 359:895-905. Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network.
46. Marret S., Marpeau L., Follet-Bouhamed C., et al. Gynecol Obstet Fertil 2008, 36:278-288. PREMAG Trial Group, [in French].
47. Palisano R., Rosenbaum P., Walter S., et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997, 39:214-223.
48. Doyle L.W., Crowther C.A., Middleton P., et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009, 1. CD004661.
49. Doyle L.W., Crowther C.A., Middleton P., et al. Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review. Obstet Gynecol 2009, 113:1327-1333.
50. Costantine M.M., Weiner S.J., Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants. Obstet Gynecol 2009, 114:354-364.
51. Conde-Agudelo A., Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Am J Obstet Gynecol 2009, 200:595-609.
52. American College of Obstetricians and Gynecologists Magnesium sulfate before anticipated preterm birth for neuroprotection. Committee Opinion No. 455. Obstet Gynecol 2010, 115:669-671.
53. Rouse D.J., Hirtz D.G., Thom E.A. Magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2009, 360:190. Reply to Mittendorf R, Pryde P.
54. Cahill A.G., Caughey A.B. Magnesium for neuroprophylaxis: fact or fiction?. Am J Obstet Gynecol 2009, 200:590-594.
55. Scott J. Magnesium sulfate for neuroprotection. What do we do now?. Obstet Gynecol 2009, 114:500-501.